Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies.
Xie Z, Saliba AN, Abeykoon J, Majeed U, Almquist DR, Wiedmeier-Nutor JE, Bezerra E, Andrade-Gonzalez X, Hickman A, Sorenson K, Rakshit S, Wee C, Tella SH, Kommalapati A, Abdallah N, Pritchett J, De Andrade M, Uprety D, Badley A, Manochakian R, Ailawadhi S, Bryce AH, Hubbard JM, Gangat N, Thompson CA, Witzig TE, McWilliams RR, Leventakos K, Halfdanarson TR. Xie Z, et al. Among authors: abeykoon j. JCO Oncol Pract. 2021 Sep;17(9):e1382-e1393. doi: 10.1200/OP.21.00177. Epub 2021 Jun 14. JCO Oncol Pract. 2021. PMID: 34125579 Free PMC article.
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
Friedman JS, Durham BH, Reiner AS, Yabe M, Petrova-Drus K, Dogan A, Pulitzer M, Busam KJ, Francis JH, Rampal RK, Ulaner GA, Reddy R, Yeh R, Hatzoglou V, Lacouture ME, Rotemberg V, Mazor RD, Hershkovitz-Rokah O, Shpilberg O, Goyal G, Go RS, Abeykoon JP, Rech K, Morlote D, Fidai S, Gannamani V, Zia M, Abdel-Wahab O, Panageas KS, Rosenblum MK, Diamond EL. Friedman JS, et al. Among authors: abeykoon jp. Br J Haematol. 2024 Jul;205(1):127-137. doi: 10.1111/bjh.19462. Epub 2024 Apr 12. Br J Haematol. 2024. PMID: 38613141
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Paludo J, et al. Among authors: abeykoon jp. Br J Haematol. 2017 Oct;179(1):98-105. doi: 10.1111/bjh.14826. Epub 2017 Aug 8. Br J Haematol. 2017. PMID: 28786474 Free article.
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. Abeykoon JP, et al. Am J Hematol. 2018 Feb;93(2):187-194. doi: 10.1002/ajh.24955. Epub 2017 Nov 17. Am J Hematol. 2018. PMID: 29080258 Free article.
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Paludo J, et al. Among authors: abeykoon jp. Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3. Ann Hematol. 2018. PMID: 29610969
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Abeykoon JP, et al. Am J Hematol. 2018 Nov;93(11):1384-1393. doi: 10.1002/ajh.25254. Epub 2018 Oct 2. Am J Hematol. 2018. PMID: 30121949 Free article.
The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.
Abeykoon JP, Paludo J, Nowakowski KE, Stenson MJ, King RL, Wellik LE, Wu X, Witzig TE. Abeykoon JP, et al. Blood Cancer J. 2019 Feb 26;9(3):24. doi: 10.1038/s41408-019-0188-6. Blood Cancer J. 2019. PMID: 30808874 Free PMC article. No abstract available.
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, Wellik L, Li Y, Krull J, Wenzl K, Novak AJ, Ansell SM, Bishop GA, Billadeau DD, Peng KW, Giles F, Schmitt DM, Witzig TE. Wu X, et al. Among authors: abeykoon j. Blood. 2019 Jul 25;134(4):363-373. doi: 10.1182/blood.2018874560. Epub 2019 May 17. Blood. 2019. PMID: 31101621 Free PMC article.
101 results